BR0317359A - Uso de ácidos alfa-feniltiocarboxìlico e alfa-feniloxicarboxìlico com atividade de diminuição de glicose no soro e diminuição de lipìdios no soro - Google Patents
Uso de ácidos alfa-feniltiocarboxìlico e alfa-feniloxicarboxìlico com atividade de diminuição de glicose no soro e diminuição de lipìdios no soroInfo
- Publication number
- BR0317359A BR0317359A BR0317359-3A BR0317359A BR0317359A BR 0317359 A BR0317359 A BR 0317359A BR 0317359 A BR0317359 A BR 0317359A BR 0317359 A BR0317359 A BR 0317359A
- Authority
- BR
- Brazil
- Prior art keywords
- alpha
- serum
- phenylthiocarboxylic
- phenyloxycarboxylic
- acids
- Prior art date
Links
- 210000002966 serum Anatomy 0.000 title abstract 4
- 239000002253 acid Substances 0.000 title abstract 3
- 150000007513 acids Chemical class 0.000 title abstract 2
- 230000000694 effects Effects 0.000 title abstract 2
- 150000002632 lipids Chemical class 0.000 title abstract 2
- 230000010030 glucose lowering effect Effects 0.000 title 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 2
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/132—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing rings
- C07C53/134—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing rings monocyclic
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Ophthalmology & Optometry (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Indole Compounds (AREA)
- Pyrane Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT000629A ITRM20020629A1 (it) | 2002-12-19 | 2002-12-19 | Uso di acidi alfa-feniltiocarbossilici e alfa-fenilossicarbossilici ad attivita' ipoglicemizzante e/o ipolipidemizzante. |
| PCT/IT2003/000820 WO2004056355A1 (en) | 2002-12-19 | 2003-12-16 | USE OF α-PHENYLTHIOCARBOXYLIC AND α-PHENYLOXYCARBOXYLIC ACIDS WITH SERUM-GLUCOSE-LOWERING AND SERUM-LIPID-LOWERING ACTIVITY |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0317359A true BR0317359A (pt) | 2005-11-08 |
Family
ID=32676886
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0317359-3A BR0317359A (pt) | 2002-12-19 | 2003-12-16 | Uso de ácidos alfa-feniltiocarboxìlico e alfa-feniloxicarboxìlico com atividade de diminuição de glicose no soro e diminuição de lipìdios no soro |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US7375124B2 (https=) |
| EP (1) | EP1572180B1 (https=) |
| JP (1) | JP2006512362A (https=) |
| KR (1) | KR20050085222A (https=) |
| CN (1) | CN100393309C (https=) |
| AR (1) | AR042547A1 (https=) |
| AT (1) | ATE423558T1 (https=) |
| AU (1) | AU2003288546B8 (https=) |
| BR (1) | BR0317359A (https=) |
| CA (1) | CA2506627A1 (https=) |
| DE (1) | DE60326382D1 (https=) |
| DK (1) | DK1572180T3 (https=) |
| ES (1) | ES2321708T3 (https=) |
| IT (1) | ITRM20020629A1 (https=) |
| MX (1) | MXPA05005848A (https=) |
| PL (1) | PL378414A1 (https=) |
| PT (1) | PT1572180E (https=) |
| SI (1) | SI1572180T1 (https=) |
| TW (1) | TWI308564B (https=) |
| WO (1) | WO2004056355A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006045010A2 (en) * | 2004-10-20 | 2006-04-27 | Resverlogix Corp. | Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases |
| PT2118074E (pt) | 2007-02-01 | 2014-03-20 | Resverlogix Corp | Compostos para a prevenção e tratamento de doenças cardiovasculares |
| SI2346837T1 (sl) | 2008-06-26 | 2015-05-29 | Resverlogix Corporation | Postopki pripravljanja kinazolinonskih derivatov |
| CA2736229C (en) * | 2008-09-05 | 2015-06-09 | Acucela Inc. | Sulfur-linked compounds for treating opthalmic diseases and disorders |
| US8952021B2 (en) | 2009-01-08 | 2015-02-10 | Resverlogix Corp. | Compounds for the prevention and treatment of cardiovascular disease |
| KR101913109B1 (ko) | 2009-03-18 | 2018-10-31 | 리스버로직스 코퍼레이션 | 신규한 소염제 |
| US9757368B2 (en) | 2009-04-22 | 2017-09-12 | Resverlogix Corp. | Anti-inflammatory agents |
| CA2851996C (en) | 2011-11-01 | 2020-01-07 | Resverlogix Corp. | Pharmaceutical compositions for substituted quinazolinones |
| US9765039B2 (en) | 2012-11-21 | 2017-09-19 | Zenith Epigenetics Ltd. | Biaryl derivatives as bromodomain inhibitors |
| US9073878B2 (en) | 2012-11-21 | 2015-07-07 | Zenith Epigenetics Corp. | Cyclic amines as bromodomain inhibitors |
| JP2016507496A (ja) | 2012-12-21 | 2016-03-10 | ゼニス・エピジェネティクス・コーポレイションＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｃｏｒｐ． | ブロモドメイン阻害剤としての新規複素環式化合物 |
| US10111885B2 (en) | 2015-03-13 | 2018-10-30 | Resverlogix Corp. | Compositions and therapeutic methods for the treatment of complement-associated diseases |
| CN114901641B (zh) * | 2020-02-28 | 2025-06-17 | 四川科伦博泰生物医药股份有限公司 | 芳香族化合物及其药物组合物和用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB860303A (en) * | 1958-06-20 | 1961-02-01 | Ici Ltd | Pharmaceutical compositions comprising ª‡-aryloxy-aliphatic carboxylic acids and/or ª |
| GB1121722A (en) * | 1966-03-31 | 1968-07-31 | Ici Ltd | New carboxylic acid derivatives |
| GB1422679A (en) * | 1972-11-16 | 1976-01-28 | Funai Pharmaceutical Ind Ltd | Substituted phenoxy-a-methylpropionic acid derivatives and a process for producing the same |
| FR2285859A1 (fr) * | 1974-09-30 | 1976-04-23 | Lafon Labor | Phenylsulfinyl-amidines et derives |
| ITRM20020014A1 (it) * | 2002-01-15 | 2003-07-15 | Sigma Tau Ind Farmaceuti | Derivati di acidi a-feniltiocarbossilici e a-fenilossicarbossilici utili per il trattamento di patologie che rispondono all'attivazione del |
-
2002
- 2002-12-19 IT IT000629A patent/ITRM20020629A1/it unknown
-
2003
- 2003-12-16 DK DK03780669T patent/DK1572180T3/da active
- 2003-12-16 CA CA002506627A patent/CA2506627A1/en not_active Abandoned
- 2003-12-16 CN CNB200380106699XA patent/CN100393309C/zh not_active Expired - Fee Related
- 2003-12-16 PT PT03780669T patent/PT1572180E/pt unknown
- 2003-12-16 AT AT03780669T patent/ATE423558T1/de not_active IP Right Cessation
- 2003-12-16 AU AU2003288546A patent/AU2003288546B8/en not_active Ceased
- 2003-12-16 MX MXPA05005848A patent/MXPA05005848A/es active IP Right Grant
- 2003-12-16 KR KR1020057009770A patent/KR20050085222A/ko not_active Ceased
- 2003-12-16 ES ES03780669T patent/ES2321708T3/es not_active Expired - Lifetime
- 2003-12-16 EP EP03780669A patent/EP1572180B1/en not_active Expired - Lifetime
- 2003-12-16 BR BR0317359-3A patent/BR0317359A/pt not_active IP Right Cessation
- 2003-12-16 WO PCT/IT2003/000820 patent/WO2004056355A1/en not_active Ceased
- 2003-12-16 JP JP2004561981A patent/JP2006512362A/ja active Pending
- 2003-12-16 SI SI200331556T patent/SI1572180T1/sl unknown
- 2003-12-16 PL PL378414A patent/PL378414A1/pl unknown
- 2003-12-16 DE DE60326382T patent/DE60326382D1/de not_active Expired - Lifetime
- 2003-12-16 US US10/539,833 patent/US7375124B2/en not_active Expired - Fee Related
- 2003-12-18 TW TW092136024A patent/TWI308564B/zh not_active IP Right Cessation
- 2003-12-19 AR ARP030104731A patent/AR042547A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CN1728992A (zh) | 2006-02-01 |
| AU2003288546B2 (en) | 2009-04-30 |
| US20060154979A1 (en) | 2006-07-13 |
| EP1572180A1 (en) | 2005-09-14 |
| ATE423558T1 (de) | 2009-03-15 |
| US7375124B2 (en) | 2008-05-20 |
| ITRM20020629A1 (it) | 2004-06-20 |
| CN100393309C (zh) | 2008-06-11 |
| DE60326382D1 (de) | 2009-04-09 |
| EP1572180B1 (en) | 2009-02-25 |
| PL378414A1 (pl) | 2006-04-03 |
| HK1087007A1 (en) | 2006-10-06 |
| MXPA05005848A (es) | 2005-08-26 |
| ES2321708T3 (es) | 2009-06-10 |
| TWI308564B (en) | 2009-04-11 |
| JP2006512362A (ja) | 2006-04-13 |
| WO2004056355A1 (en) | 2004-07-08 |
| SI1572180T1 (sl) | 2009-06-30 |
| PT1572180E (pt) | 2009-05-04 |
| CA2506627A1 (en) | 2004-07-08 |
| AU2003288546B8 (en) | 2009-06-11 |
| TW200420531A (en) | 2004-10-16 |
| DK1572180T3 (da) | 2009-06-02 |
| KR20050085222A (ko) | 2005-08-29 |
| AR042547A1 (es) | 2005-06-22 |
| AU2003288546A1 (en) | 2004-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0317359A (pt) | Uso de ácidos alfa-feniltiocarboxìlico e alfa-feniloxicarboxìlico com atividade de diminuição de glicose no soro e diminuição de lipìdios no soro | |
| BR9910928A (pt) | Composto, processo para a prepará-lo, uso do mesmo, formulação, e, processo para a profilaxia e/ou tratamento de condições clinicas associadas com resistência a insulina | |
| BRPI0513752A (pt) | derivado de ciclohexano, pró-droga do mesmo e sal do mesmo e agente terapêutico contendo o mesmo para diabetes | |
| DE59410429D1 (de) | Arzneimittel zur Behandlung des Diabes mellitus sowie seiner Folgeerkrankungen | |
| BR0306880A (pt) | Derivados do ácido fenil(alquil)carboxìlico e derivados diÈnicos de fenilalquila heterocìclica e o uso dos mesmos como medicamentos com atividade de redução de glicose do soro e/ou de lipìdios no soro | |
| BR0015048A (pt) | Sal farmacêutico, medicamento, uso de pelo menos um sal de tramadol e formas de apresentação | |
| HRP20181025T1 (hr) | Farmaceutski pripravak koji sadrži glp-1-agonist, inzulin, te metionin | |
| GT200200188A (es) | Preparacion y uso de derivados de imidazol para el tratamiento de la obesidad | |
| BRPI0406499A (pt) | Insulina de longa atuação para redução da morbidez e mortalidade cardiovascular em pacientes pré-diabéticos e pacientes com diabetes tipo 2 | |
| BR0016135A (pt) | Forma de tamanho de partìcula reduzido, uso de uma substância, composição farmacêutica, métodos para o tratamento ou a profilaxia de condições associadas com reduzida sensibilidade à insulina e de deslipidemia, diabetes melito do tipo ii, hiperglicemia, hiperinsulinemia, hipertensão arterial e/ou obesidade abdominal e processo para a preparação de um composto | |
| BR0313290A (pt) | Derivado de pirazol, composição medicinal contendo o mesmo, uso medicinal dele, e intermediário para a sua produção | |
| MY142830A (en) | Propionic acid derivatives useful in the treatment of lipid disorders | |
| BRPI0013667B8 (pt) | derivados de glucopiranosiloxipirazol, composições medicinais contendo os mesmos e seus intermediários na produção deles | |
| BRPI0517803A (pt) | pirazolpirimidinas 1,4-substituìdas como inibidores de cinase | |
| BR0013368A (pt) | Uso de um composto, composto, e, composição farmacêutica | |
| WO2002044192A1 (en) | Glucopyranosyloxybenzyl benzene derivatives, medicinal compositions containing the same and intermediates in the production thereof | |
| BR0016131A (pt) | Forma cristalina, formulação farmacêutica, uso de uma forma cristalina, uso de uma substância, métodos para tratamento ou a profilaxia de, condições associadas com reduzida sensibilidade à insulina, e de deslipidemia, diabetes melito do tipo 2, hiperglicemia, hiperinsulinemia, hipertensão arterial e/ou obesidade abdominal, e , processo para a preparação de uma forma cristalina de um composto de fórmula i | |
| BR0211414A (pt) | Composto, uso do mesmo, composição farmacêutica, e, métodos para o tratamento e/ou prevenção de condições mediadas pelos receptores nucleares e de diabetes tipo i, diabetes tipo ii, tolerância à glicose, resistência à insulina ou obesidade prejudicadas | |
| BRPI0408920A (pt) | difenilazetidinona com propriedades fisiológicas aperfeiçoadas, processo para a sua preparação, medicamentos contendo esses compostos e sua aplicação | |
| BRPI0511136A (pt) | formulações em pó para inalação contendo beta-agonistas enantiÈmeros puros | |
| BR0209711A (pt) | Composto heterocìclico e seu uso medicinal | |
| BR0210123A (pt) | Composto, formulação farmacêutica, e, uso de um composto | |
| BR0112381A (pt) | Componente farmacêutico com base em hormÈnio da paratireóide humana e uma composição farmacêutica para administração intranasal compreendendo o componente | |
| NO20054381L (no) | 1,3-substituerte sykloalkylderivater med sure, som oftest heterosykliske grupper, deres fremstilling og deres anvendelse som legemiddel | |
| Cucinotta et al. | Biphasic insulin aspart in the treatment of type 2 diabetes mellitus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 8A ANUIDADE(S). |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2144 DE 07/02/2012. |